Trial reportAcademic pediatrics2026
Personalized ADHD Medication Experiments to Inform Decisions About Continued Medication Use: An Open-Label Trial.
Trial report in Academic pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo pilot test personalized stimulant medication experiments among children 11 to 15 years old with ADHD who questioned maintaining their current medication regimen.
methodsOpen-label trial involving 30 children (63.3% male, 86.7% white) and their parents. Experiments involved tracking personally meaningful measures daily for 2 weeks on their current regimen and 2 to 4 weeks after making a change. Validated outcome measures included the Decisional Conflict Scale (DCS) and the Decision-Making Involvement Scale (DMIS).
resultsParticipants selected 1 of 5 experiments: 1) try different dose or medication (50.0%); 2) start taking medicine on non-school days (20.0%); 3) stop taking medicine on non-school days (16.7%); 4) discontinue medicine (6.7%); and 5) no change (6.7%). Parents and children completed 92.8% (standard deviation [SD] = 7.5) of daily tracking questions. Following the experiment, 46.7% chose to continue the regimen tried during the experiment, 23.3% returned to their previous regimen, and 30.0% returned to their primary care provider to discuss other options. Participants felt less conflicted about treatment pre- to post-experiment, with parent mean (SD) pre DCS score = 15.9 (13.7)→post = 9.3 (10.0), P = .01; child pre DCS score = 26.3 (11.6)→post = 22.5 (13.1), P = .12. The mean (SD) DMIS subscale score for parents seeking information/opinions from their child increased from pre-to-post-experiment based on reports from children (pre = 2.6 (0.8), post = 2.9 (0.7), P = .03) but not parents (pre = 2.6 (0.7), post = 2.6 (0.7), P = .48). Most parents (83.3%) and children (76.7%) rated the medication experiment as helpful to extremely helpful.
conclusionsPersonalized medication experiments show promise to support the transition from family- to self-management of ADHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.